文献速递骨质疏松与代谢性骨病

美国骨质疏松成人血清碱性磷酸酶水平与骨密度、骨质疏松患病率及死亡率的关联:基于NHANES 2005-2018的证据

Association of serum alkaline phosphatase levels with bone mineral density, osteoporosis prevalence, and mortality in US adults with osteoporosis: evidence from NHANES 2005-2018.
PubMed 文献 · Osteoporos Int · 2024-11-29

基于NHANES 2005-2018数据,纳入13724名18至85岁成人(其中944例骨质疏松,中位随访133个月期间221例死亡),分析血清总碱性磷酸酶(T-ALP)与骨密度、骨质疏松患病率及骨质疏松患者全因死亡率的关系。结果显示,T-ALP升高与股骨颈和腰椎骨密度降低及骨质疏松患病风险增加显著相关,且在骨质疏松患者中与全因死亡率升高相关。

要点

  • 血清T-ALP升高与股骨颈和腰椎骨密度降低显著相关,且在年龄、性别、种族和BMI亚组中结果一致。
  • T-ALP每增加1个标准差,骨质疏松患病率增加0.5%[OR(95%CI):1.005(1.005,1.005),p<0.001]。
  • 在骨质疏松患者中,T-ALP每增加1个标准差,全因死亡率增加0.4%[HR(95%CI):1.004(1.002,1.006),p<0.001]。

核心结论

  • 基于美国成人代表性样本,血清T-ALP升高与所有参与者骨密度降低及骨质疏松风险增加显著相关,并与骨质疏松患者全因死亡率升高相关。

研究设计与样本

  • 研究数据来自NHANES 2005-2018,纳入13724名18至85岁成人,其中944例诊断为骨质疏松,死亡数据来自国家死亡索引截至2019年12月31日。
  • 采用线性回归模型、亚组分析、协方差分析和加权逻辑回归模型评估T-ALP与骨密度及骨质疏松风险的关系,采用Kaplan-Meier曲线、Cox比例风险模型和限制性立方样条回归模型分析T-ALP与死亡率的关系。

主要发现

  • 在全部参与者中,血清T-ALP升高与股骨颈和腰椎低骨密度显著相关,且在年龄、性别、种族和BMI亚组中结果一致。
  • T-ALP每增加1个标准差,骨质疏松患病率增加0.5%[OR(95%CI):1.005(1.005,1.005),p<0.001]。
  • 在骨质疏松患者中,T-ALP每增加1个标准差,全因死亡率增加0.4%[HR(95%CI):1.004(1.002,1.006),p<0.001]。
  • 与血清T-ALP最低水平(<53 IU/L)参与者相比,最高水平(>79 IU/L)参与者骨质疏松患病率升高[OR(95%CI):1.292(1.021,1.636),p=0.033],全因死亡率升高[HR(95%CI):1.232(1.041,1.459),p=0.015]。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study examined the association of serum total alkaline phosphatase (T-ALP) with bone mineral density (BMD) and osteoporosis prevalence in the general population, and investigated its association with mortality in individuals with osteoporosis, using data from the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2018. Elevated serum T-ALP levels were significantly associated with both reduced BMD and an increased risk of osteoporosis in all participants. Moreover, elevated T-ALP levels were linked to higher all-cause mortality among individuals with osteoporosis during this period. INTRODUCTION: The evidence regarding the association between serum T-ALP, BMD and osteoporosis prevalence in general population is incomplete, and limited evidence is available concerning its association with mortality among individuals with osteoporosis. The study investigated the association of serum T-ALP with BMD and osteoporosis prevalence in the general population, and examined its association with mortality in individuals with osteoporosis. METHODS: All participants were adults from the NHANES (2005-2018), and mortality data were obtained from the National Death Index up to December 31, 2019. Firstly, the association of serum T-ALP with BMD and osteoporosis risk was assessed using linear regression model, subgroup analysis, analysis of covariance and weighted logistic regression model, respectively. Secondly, survival analysis including Kaplan-Meier curves, Cox proportional hazards models, and restricted cubic spline regression models were utilized to analyze the relationship between serum T-ALP levels and mortality risk. RESULTS: The study included 13,724 participants aged 18 to 85 years, and 944 were diagnosed with osteoporosis, among whom 221 died during a median of 133 months follow-up. Totally, elevated serum T-ALP was significantly associated with low BMD in femoral neck and lumbar spine, and the results exhibited consistency across diverse age, genders, races, and BMI subgroups. Moreover, for each 1 SD increase in T-ALP, there was a 0.5% increase in the prevalence of osteoporosis [OR (95%CI): 1.005 (1.005, 1.005), p < 0.001]. Among individuals with osteoporosis, for every 1 SD increase in T-ALP, the all-cause mortality increased by 0.4% [HR (95%CI):1.004 (1.002, 1.006), p < 0.001]. Meanwhile, comparing participants with highest serum T-ALP levels (> 79 IU/L) to those with lowest levels (< 53 IU/L) further raised the prevalence of osteoporosis [OR (95%CI):1.292 (1.021, 1.636), p = 0.033] and all-cause mortality [HR (95% CI):1.232 (1.041, 1.459), p = 0.015]. CONCLUSIONS: Based on a representative sample of US adults, elevated serum T-ALP levels were found to be significantly associated with both reduced BMD and an increased risk of osteoporosis across all participants, as well as with a higher all-cause mortality in individuals with osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen R, Gong K, Chen W, et al. Association of serum alkaline phosphatase levels with bone mineral density, osteoporosis prevalence, and mortality in US adults with osteoporosis: evidence from NHANES 2005-2018. Osteoporos Int. 2024. PMID: 39611944. doi:10.1007/s00198-024-07324-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。